Objective: To estimate the risk of stroke associated with new antidepressant use among older adults with traumatic brain injury (TBI). Participants: A total of 64 214 Medicare beneficiaries aged 65 years or older meeting inclusion criteria and hospitalized with a TBI during 2006 to 2010. Design: New user design. Generalized estimating equations were used to estimate the relative risks (RRs) of stroke. Main Measures: Primary exposure was new antidepressant use following TBI identified through Medicare part D claims. The primary outcome was stroke following TBI. Ischemic and hemorrhagic strokes were secondary outcomes. Results: A total of 20 859 (32%) beneficiaries used an antidepressant at least once following TBI. Selective serotonin reuptake inhibitors accounted for the majority of antidepressant use. Selective serotonin reuptake inhibitor use was associated with an increased risk of hemorrhagic stroke (RR, 1.26; 95% confidence interval [CI], 1.06-1.50) but not ischemic stroke (RR, 1.04; 95% CI, 0.94-1.15). The selective serotonin reuptake inhibitors escitalopram (RR, 1.33; 95% CI, 1.02-1.74) and sertraline (RR, 1.46; 95% CI, 1.10-1.94) were associated with an increase in the risk of hemorrhagic stroke. Conclusion: Findings from this study will aid prescribers in choosing appropriate antidepressants to treat depression in older adults with TBI.
T RAUMATIC BRAIN INJURY (TBI) is a major
health problem among older adults. 1, 2 In the United States, more than 50% of TBIs occur in adults aged 50 years and older. 3 Moreover, the rates of TBI hospitalization and mortality among adults older than 65 years are greater than those of the general population. [4] [5] [6] Traumatic brain injury is associated with an increased risk of stroke. [7] [8] [9] A large study conducted in the United States reported a significant increase in the hazard of stroke among patients with TBI aged 50 years and older compared with trauma patients without TBI. 7 A study of Medicare beneficiaries aged 65 years and older compared the rates of ischemic and hemorrhagic stroke prior to and following TBI and reported hazard rates
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through December 31, 2010 . Traumatic brain injury was defined using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 800.xx, 801.xx, 803.xx, 804.xx, 850.xx, 854.1x, 950.1-950.3, and 959.01 in any position. The Centers for Disease Control and Prevention uses these codes to define TBI, and they have been reported to have high sensitivity and positive predictive value to detect moderate to severe TBI when compared with medical records. 18, 19 Any TBI occurring within 14 days of the previous TBI was collapsed as a single TBI event.
We used a nested-cohort study with a new user design to assess the risk of stroke associated with new use of antidepressants among Medicare beneficiaries hospitalized with TBI. In a nested cohort study, all study participants have an initial exposure, in this case TBI, and then a second exposure is examined, in this case new antidepressant use. The new user study design created a wash-out period during which there could be no antidepressant use. This ensured that all antidepressant users were "new" and helped in reducing prevalent user bias. Prevalent user bias occurs when inclusion of prevalent users biases study results by underestimating early adverse events related to the study drug(s). 20 New use of antidepressants was defined as any use after a 6-month washout period.
We required at least 6 months of Medicare parts A, B, and D coverage prior to TBI. We also required continuous Medicare parts A, B, and D coverage following TBI. Beneficiaries with any antidepressant use 6 months prior to their TBI were excluded. Beneficiaries also were excluded if they did not survive the TBI hospital stay and if they had Medicare part C (Medicare Advantage) coverage because their administrative claims are not consistently available.
Exposure
The exposure of interest for this study was SSRI use following TBI. Selective serotonin reuptake inhibitor use was ascertained per 30-day period before and after the TBI hospitalization by searching Medicare part D claims. Prescriptions filled and proportion of days covered (PDC) information was used to determine SSRI use per period. Proportion of days covered information was calculated as the number of days a drug was available divided by the number of days in a period. Beneficiaries who had an SSRI prescription filled during a 30-day period or had a PDC greater than 0 were classified as SSRI users for that period. Both prescriptions filled and PDC information were used to determine SSRI use. This was because some prescriptions may be written for multiple months; therefore, while there may not have been a prescription filled every month, there could be a PDC greater than 0 for the month. Medicare beneficiaries with a skilled nursing facility (SNF) stay following TBI discharge had missing information for SSRI use up to the first 100 days of a SNF stay as medication information could not be ascertained.
Similarly, we assessed use of other antidepressants, including serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tetracyclic antidepressants (TetCAs), phenylpiperazine antidepressants (PPAs), and monoamine oxidase inhibitors (see Table 1 ). A small proportion (ranging from 2% to 5% over the course of study follow-up) of beneficiaries who had concomitant use of 2 or more different antidepressant classes were excluded from analysis because the class effects of antidepressants could not be distinguished.
Outcome
The outcome of interest for the study was stroke. Stroke was defined by inpatient claims using ICD-9-CM codes 430.xx-432.xx (hemorrhagic stroke) and 433.xx, 434.xx, 435.xx, 437.0x, and 437.1x (ischemic stroke) in any position. These codes have been used in prior Medicare claims analysis and have shown to accurately detect 21, 22 We also examined the risk of hemorrhagic and ischemic stroke separately.
Covariates
Demographic characteristics included age, sex, and race. The CCW identifies chronic conditions through Medicare claims using ICD-9-CM-based algorithms. 23 Chronic Condition Data Warehouse data identify the date of first diagnosis of a condition going back to 1999 and contain annual flags indicating that the algorithm was met for the condition. 24 Beneficiaries were categorized as having a chronic condition at baseline if the date of first diagnosis of the condition were prior to TBI. Other conditions that may be associated with stroke were identified by searching inpatient claims data for the following ICD-9-CM codes: 286. 21, 25, 26 Length of hospital stay and discharge to an SNF were included as covariates as they may be indicative of TBI severity. 21 Depression is an important confounder because it has been independently linked to an increased risk of stroke and is highly correlated with antidepressant use. [27] [28] [29] We used the CCW date of first diagnosis of depression in conjunction with annual flags to create 2 depression variables. We created an indicator variable for history of depression prior to TBI using the first ever diagnosis of depression flag and a second variable indicating recently diagnosed depression following TBI using the annual depression flags.
Statistical analysis
Associations between antidepressant use and demographic variables were tested using χ 2 and Student t tests. Trends in antidepressant use throughout the study period were assessed using the Cochran trend test.
Discrete time analysis was used to quantify the risk of stroke associated with antidepressant use. Discrete time analysis is a type of survival analysis that can be used with longitudinal data to assess the impact of time-varying exposures and covariates. 30 The risk of all stroke, ischemic stroke, and hemorrhagic stroke per period following TBI as a function of SSRI use was modeled using generalized estimating equations with a binomial distribution and complimentary log-log link. Generalized estimating equation models the correlation between multiple observations per Medicare beneficiary and can be used with longitudinal data. 31 Selective serotonin reuptake inhibitor use was lagged by 1 period to ensure that antidepressant exposure preceded the outcome. Thus, the risk of stroke was modeled on the basis of exposure to SSRIs in the preceding period. Beneficiaries were censored after experiencing the event, at death, or at the end of the study period. Potential covariates and confounders identified in literature and bivariate analysis were included in the adjusted models. We also modeled the risk of stroke as a function of other antidepressant class use. Relative risks (RRs) and 95% confidence intervals (CIs) were reported.
To better understand stroke risk associated with SSRI use, we examined the risk of ischemic and hemorrhagic stroke associated with individual SSRIs using discrete time analysis and lagging use by 1 period.
Sensitivity analysis was conducted by incorporating inverse probability treatment weights. Inverse probability treatment weights were used to control for selection bias due to the nonrandom assignment of treatment. 32 Separate inverse probability treatment weights were constructed for ischemic stroke, hemorrhagic stroke, and any stroke by first modeling antidepressant use as a function of risk factors associated with ischemic stroke, hemorrhagic stroke, and any stroke, respectively, and then calculating the inverse probability of antidepressant treatment. The weights were normalized prior to their incorporation in the models.
All analyses were performed with SAS version 9.2 (Cary, North Carolina). This study was approved by the University of Maryland, Baltimore's institutional review board. Statistical significance was set at P < .001.
RESULTS
A total of 105 315 Medicare beneficiaries meeting inclusion criteria were hospitalized for a TBI during 2006 to 2010. The study sample consisted of 64 214 beneficiaries with no antidepressant use during the 6 months prior to TBI. Among these, 43 355 (68%) did not use antidepressants following TBI (unexposed) and 20 859 (32%) used an antidepressant (exposed) at least once following TBI (see Table 2 ). Abbreviations: PPA, phenylpiperazine antidepressants; SNRI, serotonin norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; TetCA, tetracyclic antidepressant. a Numbers associated with specific drug classes reflect that total number of beneficiaries that had a fill for the specific drug class at any time following TBI. b All models adjusted for age, race, sex, warfarin use in period, length of hospital stay, discharge to a skilled nursing facility, history of depression, incident depression, atrial fibrillation, Alzheimer disease and related dementias, and hypertension. Ischemic stroke model also included hyperlipidemia, ischemic heart disease, congestive heart failure, prior ischemic stroke, and diabetes. Hemorrhagic stroke model also included liver disease, chronic kidney disease, alcohol abuse, anemia, coagulation defect, valvular heart disease, neurological disease, and prior hem stroke. All stroke models adjusted for all variables in the ischemic and hemorrhagic stroke models.
The mean age of the study population was 83 years (standard deviation, 8.0) and the sample was predominantly white (85%) and female (60%) (see Table 2 ). Compared with nonusers, antidepressant users were significantly more likely to have hypertension and atrial fibrillation, conditions that are associated with stroke. 33, 34 Antidepressant users were also more likely to have a history of depression at the time of TBI than nonusers (40% vs 17% of nonusers, P < .001). In addition, antidepressant users were more likely to have had a prior ischemic stroke (10% vs 8% of nonusers, P < .001). Antidepressant users were more likely have a longer length of TBI hospital stay (27% of antidepressant users had a stay longer than 9 days vs 23% of nonusers, P < .001). Antidepressant users were also more likely to be discharged to an SNF (44% vs 33%, P < .001) (see Table 2 ). Figure 1 displays the trends in antidepressant use among all beneficiaries during the follow-up period. Throughout the study period, SSRIs were the most commonly used antidepressant, while TCAs were the least commonly used. Selective serotonin reuptake inhibitor use steadily increased during the follow-up (P < .001). Serotonin norepinephrine reuptake inhibitor, TCA, TetCA, and PPA use also increased throughout the study period (P < .001). We did not the measure time trends or assess the risk of stroke associated with use of monoamine oxidase inhibitors because of small numbers of users.
Among antidepressant users, 949 (4.6%) had a hemorrhagic stroke and 2413 (11.7%) had an ischemic stroke. Among those who did not use antidepressants, 1448 (3.4%) had a hemorrhagic stroke and 3121 (7.5%) had an ischemic stroke.
Multivariable models
All adjusted generalized estimating equation models included age, sex, race, discharge to SNF, length of hospital stay, warfarin use in period, depression (history of and recently diagnosed), atrial fibrillation, Alzheimer disease and related dementias, and hypertension. The ischemic stroke model also included hyperlipidemia, diabetes, ischemic heart disease, congestive heart failure, and prior ischemic stroke, while the hemorrhagic stroke model also included liver disease, chronic kidney Copyright © 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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disease, neurological disease, alcohol abuse, anemia, coagulation defect, valvular heart disease, and prior hemorrhagic stroke. The composite stroke model included all variables from both ischemic and hemorrhagic stroke models.
In our adjusted models, new use of SNRIs (RR, 1.37; 95% CI, 1.10-1.72) and PPAs (RR, 1.33; 95% CI, 1.07-1.66) following TBI was associated with increased risk of our composite stroke variable (see Table 3 ). No other antidepressants were significantly associated with increased risk of stroke.
Similarly, new use of SNRIs (RR, 1.36; 95% CI, 1.06-1.73) and PPAs (RR, 1.31; 95% CI, 1.02-1.68) following TBI was associated with increased risk of ischemic stroke (see Table 3 ). No other antidepressants were significantly associated with increased risk of ischemic stroke.
New use of SSRIs (RR, 1.26; 95% CI, 1.06-1.50) following TBI was associated with an increase in the risk of hemorrhagic stroke (see Table 3 ). No other antidepressant drug class was significantly associated with an increased risk of hemorrhagic stroke. Among individual SSRIs, use of escitalopram (RR, 1.33; 95% CI, 1.02-1.74) and sertraline (RR, 1.46; 95% CI, 1.10-1.94) following TBI was associated with increased risk of hemorrhagic stroke (see Table 4 ).
In sensitivity analysis incorporating inverse probability treatment weight, PPA use increased the risk of hemorrhagic stroke (RR, 1.40; 95% CI, 1.02-1.93). All other associations remained unchanged.
DISCUSSION
In this national sample of older Medicare beneficiaries, one-third started new use of antidepressants following hospitalization for TBI, highlighting the need for information on the safety of antidepressants in this population. Selective serotonin reuptake inhibitor use was associated with an increased risk of hemorrhagic, but not ischemic, stroke. Specifically, the SSRIs escitalopram and sertraline were associated with increased risk of hemorrhagic stroke. One possible explanation for their heightened risk for stroke is that both escitalopram and sertraline decrease platelet aggregation and coagulation, increasing the risk of hemorrhage.
14 Similar to sertraline, use of both fluoxetine and paroxetine was associated with a 40% increase in risk of hemorrhagic stroke; however, these associations were not statistically significant. Throughout the study follow-up, 918 beneficiaries received fluoxetine and 1077 beneficiaries received paroxetine. Because hemorrhagic stroke is Abbreviation: SSRI, selective serotonin reuptake inhibitor. a Numbers associated with specific drugs reflect that total number of beneficiaries that had a fill for the specific drug at any time following traumatic brain injury. b All models adjusted for age, race, sex, warfarin use in period, length of hospital stay, discharge to a skilled nursing facility, history of depression, incident depression, atrial fibrillation, Alzheimer disease and related dementias, and hypertension. Ischemic stroke model also included hyperlipidemia, ischemic heart disease, congestive heart failure, prior ischemic stroke, and diabetes. Hemorrhagic stroke model also included liver disease, chronic kidney disease, alcohol abuse, anemia, coagulation defect, valvular heart disease, neurological disease, and prior hem stroke. c N/A-estimate is too small and unreliable. [35] [36] [37] [38] Two case-control studies did not find that SSRI use was associated with hemorrhagic stroke; however, those studies were not limited to the older adults. 35, 36 Two cohort studies among older adults reported that SSRI use was associated with stroke. 37, 38 No study has assessed the risk of stroke among older TBI patients who use SSRIs.
Serotonin norepinephrine reuptake inhibitor and PPA use were associated with increased risk of ischemic stroke. This may be related to their low affinity toward serotonin transporters. 16, 39, 40 Antidepressants with low affinity toward serotonin transporters may increase platelet aggregation, which can potentially increase the risk of ischemic stroke. 40 Additional analysis examining individual SNRIs and PPAs was not possible due to the small number of beneficiaries taking these antidepressants. Less than 2% of the study population was prescribed SNRIs and PPAs, suggesting that while SNRIs and PPAs may increase the risk of stroke, they are rarely prescribed in older adults with TBI.
Selective serotonin reuptake inhibitor use was not associated with an increased risk of ischemic stroke. This is important because the absolute risk of ischemic stroke is 3 1 / 2 times that of hemorrhagic stroke among older adults with TBI. 9 In this study, there were twice as many ischemic stroke events than hemorrhagic stroke events, making SSRIs a safer option for the treatment of depression for older patients with TBI compared with other antidepressant classes.
This study was limited by a lack of TBI severity information. Beneficiaries with severe TBI may be at a higher risk of stroke than those with less severe TBI. We controlled for length of hospital stay and discharge to SNF, possible proxy measures for TBI severity, in our regression models to address this limitation. This approach has been previously used in Medicare claims data. 21 Strengths of this study include a large national sample of older Medicare beneficiaries that permitted examination of the impact of individual SSRIs on the rare outcome of hemorrhagic stroke. Moreover, the nested cohort, new user study design helped reduce bias. The nested cohort design decreases selection bias as all exposure groups suffered a TBI, while the new user aspect creates a wash-out period for antidepressant users and reduces prevalent user bias. 41 Including prevalent users in a pharmacoepidemiology study may bias the results by underestimating early adverse events related to the study drug. 20 In conclusion, the SSRIs escitalopram and sertraline were associated with an increased risk of hemorrhagic stroke among older Medicare beneficiaries with TBI. Citalopram, fluoxetine, and paroxetine were not associated with increased risk of stroke and may present a safer alternative among SSRIs. Findings from this study will aid prescribers in choosing appropriate antidepressants for the treatment of depression among older adults with TBI. These findings suggest that clinicians should consider multiple factors, such as risk of stroke, when prescribing certain antidepressants to older adults with TBI.
